CorEvitas, the leading sponsor of registries in autoimmune and inflammatory diseases, and The Guthy-Jackson Charitable Foundation (GJCF) are pleased to announce that the SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions in NMOSD) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD) has reached an enrollment milestone of 200 patients.
Press
A Mediaplanet Guide to Rare Diseases. This campaign was distributed with USA Today newspaper and launched on futureofpersonalhealth.com Click here to learn more.
In this dynamic episode, Meghan explores the origin and plague of “the B word” and its cousin “difficult” and how these terms are often wrongly…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng ™(satralizumab-mwge)…
A Mediaplanet Guide to Rare Diseases. This campaign was distributed with USA Today newspaper and launched on futureofpersonalhealth.com Click here to learn more.
In this dynamic episode, Meghan explores the origin and plague of “the B word” and its cousin “difficult” and how these terms are often wrongly…
WALTHAM, Mass. and BEVERLY HILLS, Calif., March 30, 2021 /PRNewswire/ — CorEvitas and The Guthy-Jackson Charitable Foundation (GJCF) are excited to announce plans for launching the SPHERES (Synergy of Prospective Health & Experimental Research…